New Frontiers in the Treatment and Management of Amyotrophic Lateral Sclerosis (ALS): Managed Care Considerations in an Evolving Treatment Paradigm

Robert L. Sufit

New Frontiers in the Treatment and Management of Amyotrophic Lateral Sclerosis (ALS): Managed Care Considerations in an Evolving Treatment Paradigm

Robert L. Sufit^*

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › peer-review

Abstract

Although a devastating disease, there is hope for improved survival for patients with amyotrophic lateral sclerosis (ALS). Two disease-modifying therapies (DMTs), which slow the progression of the disease in addition to other interventions, have improved care for these patients. Additional agents and potentially curative gene therapies are under investigation.

Original language	English (US)
Pages (from-to)	6-9
Number of pages	4
Journal	Journal of Managed Care Medicine
Volume	24
Issue number	2
State	Published - 2021

ASJC Scopus subject areas

Health Policy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{2a14701f0b534504a3710ee364a65f3b,

title = "New Frontiers in the Treatment and Management of Amyotrophic Lateral Sclerosis (ALS): Managed Care Considerations in an Evolving Treatment Paradigm",

abstract = "Although a devastating disease, there is hope for improved survival for patients with amyotrophic lateral sclerosis (ALS). Two disease-modifying therapies (DMTs), which slow the progression of the disease in addition to other interventions, have improved care for these patients. Additional agents and potentially curative gene therapies are under investigation.",

author = "Sufit, {Robert L.}",

year = "2021",

language = "English (US)",

volume = "24",

pages = "6--9",

journal = "Journal of Managed Care Medicine",

issn = "1094-1525",

publisher = "National Association of Managed Care Physicians",

number = "2",

}

TY - JOUR

T1 - New Frontiers in the Treatment and Management of Amyotrophic Lateral Sclerosis (ALS)

T2 - Managed Care Considerations in an Evolving Treatment Paradigm

AU - Sufit, Robert L.

PY - 2021

Y1 - 2021

N2 - Although a devastating disease, there is hope for improved survival for patients with amyotrophic lateral sclerosis (ALS). Two disease-modifying therapies (DMTs), which slow the progression of the disease in addition to other interventions, have improved care for these patients. Additional agents and potentially curative gene therapies are under investigation.

AB - Although a devastating disease, there is hope for improved survival for patients with amyotrophic lateral sclerosis (ALS). Two disease-modifying therapies (DMTs), which slow the progression of the disease in addition to other interventions, have improved care for these patients. Additional agents and potentially curative gene therapies are under investigation.

UR - http://www.scopus.com/inward/record.url?scp=85168376704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85168376704&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85168376704

SN - 1094-1525

VL - 24

SP - 6

EP - 9

JO - Journal of Managed Care Medicine

JF - Journal of Managed Care Medicine

IS - 2

ER -

New Frontiers in the Treatment and Management of Amyotrophic Lateral Sclerosis (ALS): Managed Care Considerations in an Evolving Treatment Paradigm

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this